Stefan van den Eijnde
Director/Miembro de la Junta en Dutch Vaccines Group .
Perfil
Stefan van den Eijnde is Director of Business Development for MUbio Products BV.
He co-founded NovoVacs BV in 2002.
Dr. van den Eijnde received a Master's degree in Biomedical Sciences from the University of Leiden in 1992 and a PhD in 1999.
Cargos activos de Stefan van den Eijnde
| Empresas | Cargo | Inicio |
|---|---|---|
| Dutch Vaccines Group | Director/Miembro de la Junta | 01/09/2009 |
| LifetecZONe | Director/Miembro de la Junta | 17/05/2010 |
Antiguos cargos conocidos de Stefan van den Eijnde.
| Empresas | Cargo | Fin |
|---|---|---|
MUbio Holding BV
 MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Corporate Officer/Principal | 05/06/2013 |
| Maastricht University | Director Técnico/Científico/I+D | - |
| NovoVacs BV | Fundador | - |
Formación de Stefan van den Eijnde.
| University of Leiden | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
MUbio Holding BV
MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Health Technology |
| NovoVacs BV | |
| Dutch Vaccines Group | |
| LifetecZONe |
- Bolsa de valores
- Insiders
- Stefan van den Eijnde
